Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Peter A Cohen
AddedFeb 19, 2024
UpdatedMay 1, 2026
Peter A Cohen

Peter A Cohen

Board Member, PolarityTE

Peter A Cohen's Career

PolarityTE
PolarityTE

Salt Lake City, UT, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Peter A Cohen's Career

PolarityTE
PolarityTE
Public$13M421998Salt Lake City, UT, US
Board Member· Board

Leadership at PolarityTE

David SeaburgDavid SeaburgBoard Member
Richard HagueRichard HagueBoard Member
Edward SwansonEdward SwansonFounder
Willie BoganWillie BoganBoard Member

Similar to PolarityTE

BioTissueBioTissueMiami, FL, USTissue, Wound Healingest. 1997BioTissueMiami, FL, US · est. 1997

Biotissue Holdings Inc., a US-based company, specializes in regenerative wound healing using human birth tissues.

Public · $110M365
Endogena TherapeuticsEndogena TherapeuticsSan Francisco, CA, USRegenerative Medicinesest. 2016Endogena TherapeuticsSan Francisco, CA, US · est. 2016

Endogena, a biotech firm, pioneers in developing first-in-class regenerative medicines for tissue and organ repair.

Series A · $29M15
SurrozenSurrozenSouth San Francisco, CA, USRegenerative Medicinesest. 2016SurrozenSouth San Francisco, CA, US · est. 2016

Surrozen: A biotech firm innovating regenerative medicines by harnessing the body's self-renewal properties.

Public · $253M79
RegeneRx BiopharmaceuticalsRegeneRx BiopharmaceuticalsRockville, MD, USPharmaceuticals, Therapeuticsest. 1982RegeneRx BiopharmaceuticalsRockville, MD, US · est. 1982

US-based RegeneRx Biopharmaceuticals specializes in commercializing Thymosin beta 4 for rapid tissue repair and regeneration.

Public · $11.7M3

Peter A Cohen's Similar Executives & Operators

Jay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoYun SeokYun SeokBoard Member · Kakao

People Similar to Peter A Cohen

PETER ANTHONY COHENPETER ANTHONY COHENBoard Member · LinkemPhillip L CohenPhillip L CohenBoard Member · UniFirstPeter PauliPeter PauliBoard Member · SiC ProcessingPeter F SmithPeter F SmithBoard Member · CNB FinancialDr David E CohenDr David E CohenBoard Member · Topica PharmaceuticalsRobert Allen CohenRobert Allen CohenBoard Member · Gold Reserve